Dual Phase 1/2 Clinical Trial for Recurrent Glioblastoma
Brain cancers are classified by the type of cell from which they originate. Gliomas, which originate in glial cells that support and protect neurons, account for about 70 percent of brain cancers.
The Cancer Therapy & Research Center at the University of Texas Health Science Center at San Antonio is one of four National Cancer Institute designated cancer centers in Texas. CTRC is the only center in the world conducting this rare Dual Phase 1/2 clinical trial for recurrent glioblastoma. A Dual Phase 1/2 clinical trial is designed to determine the best possible dose for a new treatment and its initial efficacy.
The clinical trial is investigating the maximum tolerated dose, safety and efficacy of rhenium nanoliposomes in recurrent glioblastoma. Rhenium Nanoliposomes are a compound which releases radiation in small particles that are absorbed after only a fraction of an inch. This limited penetration means that high doses can be given without the toxicity of other forms of radiation.
The study began with David Williams, whose progress so far has been good.
Is the estimated enrollment in the trial
"You never know until you begin the studies how a human being is going to react to a new therapy, and we have to be very careful about how we proceed on that. And in this case it’s not only the therapy that’s new, it’s how it gets to the tumor." Andrew Brenner, M.D., Ph.D., neuro-oncologist at The Cancer Therapy & Research Center, leader of the clinical trial